“Following the FDA’s decision on the avasopasem NDA, we have taken decisive steps to extend our cash runway as we seek a Type A meeting with the FDA to discuss the potential path forward for approval,” said Mel Sorensen, M.D., Galera’s President and CEO. “In parallel, enrollment continues in the ongoing GRECO trials of rucosopasem, our anti-cancer candidate, as we investigate the novel compound’s potential to enhance stereotactic body radiotherapy and extend the lives of patients with deadly cancers.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GRTX:
- Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
- GRTX Earnings this Week: How Will it Perform?
- Biotech Alert: Searches spiking for these stocks today
- Galera Therapeutics downgraded to Underperform at BofA, coverage terminated
- Galera Therapeutics downgraded to Neutral from Overweight at Piper Sandler
